RJA
TNXP icon

Raymond James & Associates’s Tonix Pharmaceuticals TNXP Stock Holding History

Raymond James & Associates’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14
Closed -$70.1K – 3939
2023
Q2 		$70.1K Buy
14
+1
+8% +$7.58K ﹤0.01% 3677
2023
Q1 		$157K Buy
13
+5
+63% +$85.8K ﹤0.01% 3548
2022
Q4 		$65.5K Buy
+8
New +$69K ﹤0.01% 3695

Other funds holding TNXP

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Raymond James & Associates's TNXP Position: Q3 2023 in Review

Raymond James & Associates sold out of Tonix Pharmaceuticals (TNXP) in Q3 2023, closing a stake of 14 shares — an estimated $70.1K sold.

Raymond James & Associates first reported a position in TNXP in Q4 2022 and held it in 3 quarters. The position peaked at $157K in Q1 2023. 14 funds tracked by Wall St. Rank hold TNXP as of Q3 2023.

  • Raymond James & Associates reported no remaining Tonix Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 14 Tonix Pharmaceuticals shares in Q3 2023, an estimated $70.1K.
  • Raymond James & Associates first reported a position in Tonix Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Raymond James & Associates's Tonix Pharmaceuticals position peaked at $157K in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.